Dr. Stephen Yant to Speak at the Society for Medicines Research Award Meeting / cancer, OncoDaily, Oncology, Society for Medicines Research, Stephen Yant

K11/K48 branched ubiquitin chains regulate protein degradation and cell cycle progression. Here, the authors report the structural basis of how such a branched ubiquitin chain is recognized by the hum...

🌟 Speaker Spotlight: Target ID and Validation in Drug Discovery – Oct 24th 2025 🌟 We are excited to welcome Dr David Hulcoop, the Executive Director at Open Targets European Bioinformatics Institute...

An epitope-centric screening approach widens the neosubstrate landscape for targeted protein degradation

SNAP-tag is a widespread tool for labeling protein for bioimaging. Now, Kühn et al. report SNAP-tag2 with increased labeling kinetics and brightness, which translates into a better performance in live...

YouTube video by ukjoncollins

In target-based drug discovery, quantification of target engagement is required to build structure–activity relationships and develop a potent clinical candidate. Target engagement data also provides evidence of a drug’s mechanism of action (MoA) which although is not required for approval, can increase the chance of a successful clinical outcome. Consequently, a plethora of assays has been developed to provide information about target engagement on isolated proteins and in cells. These techniques monitor changes in stability, structure, optical properties or mass difference between proteins and their complexes with ligands. They also provide characterization of the compound with thermodynamic, kinetic and structural binding parameters. The diversity of approaches reflects the challenges faced when drugging different protein classes, with each method having advantages, trade-offs and target specificity.

🔬Join Us for the 1st SMR Women’s Health Meeting 📣 📣 📣   The SMR is delighted to launch its first Women’s Health meeting - a focused, one-day scientific event aimed at accelerating therapeutic discove...

This review discusses the cellular pathways mediating Targeted Protein Degradation approaches and points to some gaps in our understanding of the biology of novel therapeutic tools such as PROTACs.

C-Terminal cyclic imides are posttranslational modifications on proteins that are recognized and removed by the E3 ligase substrate adapter cereblon (CRBN). Despite the observation of these modificati...

The SC-pSILAC method enables single-cell measurement of both protein abundance and turnover, providing notable advances in the depth and versatility of proteomic technologies.

Congratulations to The Institute of Cancer Research for winning the Award on the category for Best Performing Non-Profit Research Organisation of the Year on…

🤝 Are you passionate about Targeted Protein Degradation and want to join us on our mission to make the discoveries that defeat cancer? Dr Agnieszka…